

K-H Peiffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4194919/publications.pdf>

Version: 2024-02-01

27
papers

400
citations

840119

11
h-index

794141

19
g-index

28
all docs

28
docs citations

28
times ranked

760
citing authors

#	ARTICLE	IF	CITATIONS
1	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. <i>Hepatology</i> , 2016, 63, 63-73.	3.6	50
2	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	3.0	50
3	No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 432-439.	1.9	39
4	Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 114-123.	1.9	37
5	Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. <i>Journal of Hepatology</i> , 2015, 62, 791-798.	1.8	33
6	Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBsAg-negative chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1523-1535.	1.9	33
7	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
8	Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes. <i>Virology</i> , 2017, 502, 1-12.	1.1	22
9	Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?. <i>Gut</i> , 2022, 71, 1036-1038.	6.1	13
10	European RAVS Database: Frequency and Characteristics of RAVS in Treatment-Naïve and DAA-Experienced Patients. <i>Journal of Hepatology</i> , 2016, 64, S139.	1.8	12
11	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
12	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1a Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
13	Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy340.	0.4	11
14	Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 940-954.	1.9	9
15	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 524-530.	0.8	7
16	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	6
17	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	5
18	The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles. <i>Cells</i> , 2020, 9, 1898.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731.	1.1	5
20	Letter: impact of <sc>HBV</sc> genotypes and <sc>PC</sc>/<sc>BCP</sc> mutations on serum <sc>HB</sc><sc>sAg</sc> levels in Chinese <sc>HB</sc><sc>eAg</sc> negative patientsâ€™ Authorsâ€™ ² reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 238-239.	1.9	3
21	Not uncommon: HBV genotype G coâ€™infections among healthy European HBV carriers with genotype A and E infection. Liver International, 2021, 41, 1278-1289.	1.9	3
22	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistanceâ€™associated substitutions. Liver International, 2020, 40, 2660-2671.	1.9	2
23	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight, 2020, 5, .	2.3	2
24	A 55-Year-Old Man with Recurrent Gastrointestinal Bleeding Due to Stricture of the Portal Vein Anastomotic Site 12 Years After Combined Pancreas and Kidney Transplantation.. American Journal of Case Reports, 2022, 23, e936148.	0.3	2
25	Reply. Hepatology, 2016, 64, 1378-1379.	3.6	0
26	Editorial: <sc>HB</sc><sc>sAg</sc> serum levels in <sc>HB</sc><sc>eAg</sc>-negative chronic <sc>HBV</sc> infectionâ€™is it a matter of genotype? Authorsâ€™ TM reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 103-104.	1.9	0
27	Editorial: HBVâ€™the naked truth? Authorsâ€™ TM reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 964-965.	1.9	0